SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

February 18, 2016 07:11 ET

Parent Advocates Join CTD Holdings Family and Physicians Listening Circle on NPC Treatment

Listening Circle International Membership Expands to Include Norway

ALACHUA, FL--(Marketwired - February 18, 2016) - CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology growth company that develops cyclodextrin-based products for the treatment of disease, today announced that T.J. Racoosin (US) and Siri Skollerud-Blegen (Norway), both parents of children with Niemann-Pick Type C disease and advocates for developing treatment and cures, have joined CTD's Family and Physicians Listening Circle. The Listening Circle is a virtual network for learning and sharing, with plans to meet in person in 2016. Ms. Racoosin will work in a volunteer capacity to organize communications for the group. 

"As we continue to establish our Trappsol® Cyclo™ product as the leading treatment for NPC, it is critical that we hear from families most impacted by the disease," said N. Scott Fine, CTD Chairman and CEO. "The energies and insights of both of our new members will add immense value to the work of the Listening Circle," added Dr. Sharon Hrynkow, a Co-Chair of the Listening Circle and CTD Senior VP for Medical Affairs. 

Niemann-Pick Type C (NPC) disease is a rare and fatal genetic disease. It impacts primarily children but is also increasingly diagnosed in older patients who may live with disability for many years. NPC impacts the brain and major organs through abnormal accumulation of cholesterol in cells. CTD is working to develop its orphan drug designated Trappsol® Cyclo™ for the treatment of NPC. 

"The Listening Circle provides families with a unique opportunity to gain an understanding of the science behind cyclodextrins, while giving families a platform to share lessons learned with other treatments and to both provide support, and gain support, in the process," said Sue French (UK), a Listening Circle Co-Chair and parent of an NPC-affected child. The third Listening Circle Co-Chair is Dr. Caroline Hastings, a treating physician at the UCSF Benioff Children's Hospital Oakland (California), who has used Trappsol® Cyclo™ in her treatment programs for NPC on a compassionate basis and who shares her protocol with physicians globally. Dr. Hastings is also a member of CTD's Scientific Advisory Board.

Other members of the Listening Circle are based in Brazil, Spain and the UK. They are a mix of treating physicians and parents of NPC patients.

About the Company: 
CTD Holdings, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company's Trappsol® Cyclo™, an orphan drug designated product in the United States and the EU, is used to treat Niemann-Pick Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company's website: www.ctd-holdings.com

Safe Harbor Statement:
This press release contains "forward-looking statements" about the company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company's future performance include the company's ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company's biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information